Clinical Trial Update: A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects [Phase 1]

View source ↗

Summary

This Phase IB trial evaluated the safety and immunogenicity of the CryJ2-DNA-LAMP plasmid in subjects with allergic rhinoconjunctivitis; the study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• CryJ2-DNA-LAMP plasmid

Snippet

Sponsor: Immunomic Therapeutics, Inc. | Conditions: Allergic Rhinoconjunctivitis | Phase 1 | Status: COMPLETED